BiotechTube
Arcedi Biotech

Arcedi Biotech

Copenhagen, Denmark· Est.
arcedi.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Arcedi Biotech, founded in 2015 and based in Copenhagen, Denmark, is a pioneer in cell-based non-invasive prenatal testing (cbNIPT). The company's proprietary platform isolates circulating fetal cells from a maternal blood draw, enabling direct, genome-wide genetic analysis of the fetus with high accuracy. This positions Arcedi to potentially disrupt the prenatal diagnostics market by offering a safer, more comprehensive alternative to invasive procedures (CVS, amniocentesis) and cell-free DNA tests. Its commercial focus is currently on its EVITA TEST product line, with a strong IP portfolio extending through 2031.

Prenatal Diagnostics

Technology Platform

Proprietary platform for isolating intact fetal cells (trophoblasts) from maternal blood for direct genetic analysis, enabling cell-based non-invasive prenatal testing (cbNIPT).

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global NIPT market is large and growing.
Arcedi's technology offers a potentially superior product with whole-genome analysis from fetal cells, positioning it to capture share from both invasive procedures and limited cfDNA tests.
Successful validation could establish a new standard of care in prenatal screening.

Risk Factors

Facing intense competition from established cfNIPT giants.
Must prove clinical utility, secure reimbursement, and scale complex cell-isolation technology cost-effectively.
As a private, early-stage company, it carries significant commercialization and execution risk.

Competitive Landscape

Competes directly with leading cfNIPT providers like Illumina (GRAIL), Natera, Roche, and BGI. Its technology differentiates by analyzing whole fetal cells, but it lacks the commercial scale, brand recognition, and payer relationships of these incumbents. It may also face future competition from other companies developing cbNIPT.

More companies in Diagnostics & Precision Medicine →More companies in Denmark →